Neurodevelopmental Disorders: Beyond protein-coding genes

A long non-coding RNA called lnc-NR2F1 regulates several neuronal genes, including some involved in autism and intellectual disabilities.
  1. Anna Lozano-Ureña
  2. Sacri R Ferrón  Is a corresponding author
  1. University of Valencia, Spain

Most of the mammalian genome does not encode for working proteins. However, much of this non-coding DNA is still transcribed, often to produce RNA products that have a role in development. Some of these molecules are called long non-coding RNAs (lncRNAs) because they contain more than 200 base pairs: these transcripts fine-tune gene expression by interacting with chromatin and the transcription machinery inside cells (Ponting et al., 2009). The brain expresses more lncRNAs than any other part of the body (Derrien et al., 2012), but we know relatively little about the roles these molecules play in this organ (D'haene et al., 2016; Aprea et al., 2013). Learning more about lncRNAs will be essential if we are to understand both the typical and the atypical brain.

In intellectual disabilities or autism spectrum disorders, defects in cognitive abilities, such as social interaction and communication, can appear early in development and persist into adulthood. These neurodevelopmental disorders involve abnormal changes in the way genetic information is expressed (Rennert and Ziats, 2017). Several lncRNAs are associated with these conditions, sometimes being transcribed atypically (reviewed in van de Vondervoort et al., 2013). For instance, certain lncRNAs are expressed differently in patients on the autism spectrum (Ziats and Rennert, 2013).

Now, in eLife, Anand Srivastava, Marius Wernig, Howard Chang and colleagues – including Cheen Ang, Qing Ma and Orly Wapinski, all from Stanford University, as joint first authors – report that several lncRNAs that are involved in the formation of neurons are mutated or disrupted in children with autism spectrum disorder and intellectual disabilities (Ang et al., 2019).

Ang et al. started by reprogramming mouse cells called embryonic fibroblasts into neurons; this experiment helped them to identify 35 candidate lncRNAs that are both upregulated when neurons form and close to neuronal genes. Amongst those, 28 were present on the same chromosomes in humans and in mice. The group then tried to identify whether these 28 human candidates were mutated in disease by overlapping the lncRNAs sequences onto a map of mutations found in children with neurodevelopmental disorders and congenital defects. This analysis highlighted five lncRNAs that were often mutated in affected individuals, and which happened to also be expressed during human brain development. One of them, called lnc-NR2F1, was adjacent to NR2F, a gene which encodes a transcription factor that helps neurons form and wire together (Borello et al., 2014).

The team, which is based at Stanford, Clemson University, the University of Washington, the Greenwood Genetic Center, and the Austrian Academy of Sciences, found patients with developmental delays who expressed normal levels of the coding NR2F1 gene but presented a unique disruption of the lnc-NR2F1 gene. Most of the brain lncRNAs are located near genes that code for proteins, and it is believed that both lncRNAs and protein-coding genes are expressed at the same time (Ponjavic et al., 2009). However, the work by Ang et al. potentially indicates that lnc-NR2F1, rather than NR2F1, might contribute to the clinical symptoms associated with neurodevelopmental disorders. If so, this would strengthen the hypothesis that lncRNAs are independent transcriptional units that activate gene expression in the brain.

Then, Ang et al. discovered that, in mouse cells, lnc-Nr2f1 enhanced the transcription of genes that create and guide the structures which allow neurons to connect. Deleting or overexpressing lnc-Nr2f1 changed how these genes were expressed, and how the cells looked and worked. In addition, lnc-Nr2f1 was shown to attach to the genes, suggesting that it binds chromatin to regulate gene expression (Figure 1). While we still do not fully understand the physiological changes that accompany neurodevelopmental disorders, the results by Ang et al. suggest that lncRNAs themselves may contribute to these conditions, or that they drive the expression of disease-associated genes.

Long non-coding RNAs (lncRNAs) and neuronal development in neurodevelopmental disorders.

Mouse embryonic fibroblasts (orange) were reprogrammed into neurons (top right) using transcription factors called BAM factors. This led to an increase in the expression of neuronal genes (green triangle) and lncRNAs (pink triangle). Of the 287 lncRNAs that were differentially expressed, 35 were close to neuronal genes. One of these, lnc-Nr2f1 (red loops), binds to mouse neuronal and axon guidance genes (black boxes) and promotes their transcription (green arrow). The overexpression of lnc-Nr2f1 resulted in 311 neuronal genes being upregulated and 32 being repressed. The expression of lnc-NR2F1 is altered (red cross) in patients with autism spectrum disorders and intellectual disabilities, and this potentially disrupts the transcription of human neuronal and axon guidance genes (brown boxes; black inhibitory arrow). It is therefore possible that lnc-NR2F1 is involved in these conditions.

How mutations in protein-coding genes contribute to disease is widely studied, yet most mutations are found in regions that do not code for proteins. Understanding how lncRNAs regulate genes during brain development provides a way to tie genetic variation with changes in gene expression in neurodevelopmental disorders. Building on the findings by Ang et al., it may be possible to examine how clinical phenotypes, cellular responses and lncRNAs are connected in these conditions, potential unearthing new targets for therapeutic intervention.

References

Article and author information

Author details

  1. Anna Lozano-Ureña

    Anna Lozano-Ureña is in the Department of Cell Biology, University of Valencia, Valencia, Spain

    Competing interests
    No competing interests declared
  2. Sacri R Ferrón

    Sacri R Ferrón is in the Department of Cell Biology and ERI BiotecMed, University of Valencia, Valencia, Spain

    For correspondence
    sacramento.rodriguez@uv.es
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0854-8575

Publication history

  1. Version of Record published:

Copyright

© 2019, Lozano-Ureña and Ferrón

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,497
    views
  • 157
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Anna Lozano-Ureña
  2. Sacri R Ferrón
(2019)
Neurodevelopmental Disorders: Beyond protein-coding genes
eLife 8:e45123.
https://doi.org/10.7554/eLife.45123

Further reading

    1. Genetics and Genomics
    Shek Man Chim, Kristen Howell ... Regeneron Genetics Center
    Research Article

    Recent studies have revealed a role for zinc in insulin secretion and glucose homeostasis. Randomized placebo-controlled zinc supplementation trials have demonstrated improved glycemic traits in patients with type II diabetes (T2D). Moreover, rare loss-of-function variants in the zinc efflux transporter SLC30A8 reduce T2D risk. Despite this accumulated evidence, a mechanistic understanding of how zinc influences systemic glucose homeostasis and consequently T2D risk remains unclear. To further explore the relationship between zinc and metabolic traits, we searched the exome database of the Regeneron Genetics Center-Geisinger Health System DiscovEHR cohort for genes that regulate zinc levels and associate with changes in metabolic traits. We then explored our main finding using in vitro and in vivo models. We identified rare loss-of-function (LOF) variants (MAF <1%) in Solute Carrier Family 39, Member 5 (SLC39A5) associated with increased circulating zinc (p=4.9 × 10-4). Trans-ancestry meta-analysis across four studies exhibited a nominal association of SLC39A5 LOF variants with decreased T2D risk. To explore the mechanisms underlying these associations, we generated mice lacking Slc39a5. Slc39a5-/- mice display improved liver function and reduced hyperglycemia when challenged with congenital or diet-induced obesity. These improvements result from elevated hepatic zinc levels and concomitant activation of hepatic AMPK and AKT signaling, in part due to zinc-mediated inhibition of hepatic protein phosphatase activity. Furthermore, under conditions of diet-induced non-alcoholic steatohepatitis (NASH), Slc39a5-/- mice display significantly attenuated fibrosis and inflammation. Taken together, these results suggest SLC39A5 as a potential therapeutic target for non-alcoholic fatty liver disease (NAFLD) due to metabolic derangements including T2D.

    1. Developmental Biology
    2. Genetics and Genomics
    Subhradip Das, Sushmitha Hegde ... Girish S Ratnaparkhi
    Research Article

    Repurposing of pleiotropic factors during execution of diverse cellular processes has emerged as a regulatory paradigm. Embryonic development in metazoans is controlled by maternal factors deposited in the egg during oogenesis. Here, we explore maternal role(s) of Caspar (Casp), the Drosophila orthologue of human Fas-associated factor-1 (FAF1) originally implicated in host-defense as a negative regulator of NF-κB signaling. Maternal loss of either Casp or it’s protein partner, transitional endoplasmic reticulum 94 (TER94) leads to partial embryonic lethality correlated with aberrant centrosome behavior, cytoskeletal abnormalities, and defective gastrulation. Although ubiquitously distributed, both proteins are enriched in the primordial germ cells (PGCs), and in keeping with the centrosome problems, mutant embryos display a significant reduction in the PGC count. Moreover, the total number of pole buds is directly proportional to the level of Casp. Consistently, it’s ‘loss’ and ‘gain’ results in respective reduction and increase in the Oskar protein levels, the master determinant of PGC fate. To elucidate this regulatory loop, we analyzed several known components of mid-blastula transition and identify the translational repressor Smaug, a zygotic regulator of germ cell specification, as a potential critical target. We present a detailed structure-function analysis of Casp aimed at understanding its novel involvement during PGC development.